Oxbryta Lawsuit Updates
Oxbryta (voxelotor), a medication developed to treat sickle cell disease (SCD), has recently become the focus of significant legal action following its global recall in September 2024. Manufactured by Pfizer, Oxbryta was initially hailed as a breakthrough treatment for SCD, a genetic disorder characterized by abnormal hemoglobin that leads to distorted, sickle-shaped red blood cells.